Abstract:The market for direct-to-consumer (DTC) health services continues to grow rapidly with former patients converting to customers for the opportunity to purchase varied diagnostic tests without the involvement of their clinician. For the first time a DTC genetic testing company is advertising health-related reports "that meet [Food and Drug Administration] standards for being clinically and scientifically valid." Ethicists and regulatory agencies alike have recognized the need for a more informed transaction in the DTC context, but how should we classify a commercial transaction for something normally protected by a duty of care? How can we assure informed agreements in an industry with terms and conditions as varied as the services performed? The doctrine of "informed consent" began as an ethical construct building on the promise of beneficence in the clinical relationship and elevating the principle of autonomy--but in the DTC context should we hold providers to legal standards of informed consent and associated medical malpractice liability, or contractual obligations where consumers would seek remedy for breach? This Article analyzes the fine balance that must be struck in an industry where companies are selling services for entertainment or non-medical purposes that possess the capacity to produce serious and disquieting medical information. It begins by reviewing current standards of consent in the clinical setting from both a legal and ethical perspective and then lays forth current standards for DTC consent using two currently controversial case studies: that of keepsake fetal ultrasound and genetic testing. DTC keepsake ultrasound and genetic testing providers attempt to de-medicalize the devices used for these procedures from their intended medical uses to non-medical uses. But while keepsake ultrasound is marketed as "intended for entertainment purposes only," it can provide medical information as an incidental finding. 23andMe currently purports to be the only DTC genetics service that "includes" reports that meet FDA qualifications, despite disclaimers of intent to "provide medical advice." The attempted de-medicalization of these devices, therefore, has not been fully transformative, and DTC providers should have more robust ethical and legal duties than the average goods and services seller. This Article delineates these responsibilities, beginning with ethical duties surrounding marketing, entering into, and providing DTC services. It then turns to the legal paradigms necessary to enable, or at least allow for, DTC providers to meet these ethical obligations. While it argues that contractual, as opposed to fiduciary, requirements are most appropriate and that waivers of liability will likely be upheld, it also advocates for a heightened expectation of disclosure during contracting.

Consumer direct access to clinical laboratory testing: what are the critical issues?

RECONCEPTUALIZING CONSENT FOR DIRECT-TO-CONSUMER HEALTH SERVICES

Facilitators of and Barriers to the Use of a Digital Self-Management Service for Diagnostic Testing: Focus Group Study With Potential Users

Unpacking the Use of Laboratory Test Results in an Online Health Community throughout the Medical Care Trajectory

Mystery patient insight into clinical laboratory service

Miniaturization and globalization of clinical laboratory activities

The dichotomy of diagnostics: exploring the value for consumers, clinicians and care pathways

Direct-to-consumer telemedicine: navigating the implications for quality and safety of care

How Consumers and Physicians View New Medical Technology: Comparative Survey

Patient Preferences for Point-of-Care Testing: Survey Validation and Results

Embracing and Advancing the Consumerist Era in Healthcare

A Changing World Demands Care That Takes a Consumer-Centric Approach

Public Perspectives on Direct-to-Consumer Testing Oversight

Genetic and Genomic Consultation: Are We Ready for Direct-to-Consumer Telegenetics?

The Impact of Direct-to-Consumer Medication and Genetic Tests on Contemporary Lives

Improved implementation of medical tests - barriers and opportunities

Direct-to-consumer tests advertised online in Australia and their implications for medical overuse: systematic online review and a typology of clinical utility

Diagnostics 4.0: the medical laboratory in digital health

Promoting Informed Choice: Transforming Health Care To Dispense Knowledge for Decision Making

Utilizing Point-of-Care Testing to Optimize Patient Care

Update on Patient Self-Testing with Portable and Wearable Devices: Advantages and Limitations